EverSource Wealth Advisors’s Pacira BioSciences PCRX Stock Holding History

EverSource Wealth Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.36K	Sell	93 -367	-80%	-$8.68K	﹤0.01%	3658
2026 Q1	$10.4K	Buy	460 +96	+26%	+$2.13K	﹤0.01%	2893
2025 Q4	$9.42K	Sell	364 -4	-1%	-$95	﹤0.01%	2831
2025 Q3	$9.48K	Sell	368 -485	-57%	-$11.9K	﹤0.01%	2847
2025 Q2	$20.4K	Buy	853 +781	+1,085%	+$19.7K	﹤0.01%	2269
2025 Q1	$1.79K	Buy	72 +24	+50%	+$575	﹤0.01%	2978
2024 Q4	$904	Buy	+48	New	+$843	﹤0.01%	3002
2024 Q1	–	Sell	-247	Closed	-$8.33K	–	2963
2023 Q4	$8.33K	Buy	+247	New	+$7.23K	﹤0.01%	1648
2023 Q2	–	Sell	-259	Closed	-$10.6K	–	2578
2023 Q1	$10.6K	Buy	+259	New	+$10.3K	﹤0.01%	1327
2022 Q4	–	Sell	-128	Closed	-$7K	–	2395
2022 Q3	$7K	Buy	128 +107	+510%	+$5.95K	﹤0.01%	1249
2022 Q2	$1K	Hold	21	–	–	﹤0.01%	1659
2022 Q1	$2K	Hold	21	–	–	﹤0.01%	1561
2021 Q4	$1K	Buy	+21	New	+$1.16K	﹤0.01%	1717

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EverSource Wealth Advisors's PCRX Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Pacira BioSciences (PCRX) stake by 80% in Q2 2026, selling an estimated $8.68K and leaving 93 shares worth $2.36K. The position accounts for ﹤0.01% of the portfolio, ranked #3658.

EverSource Wealth Advisors first reported a position in PCRX in Q4 2021 and has held it in 13 quarters since. The position peaked at $20.4K in Q2 2025. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

EverSource Wealth Advisors held 93 shares of Pacira BioSciences worth $2.36K as of Q2 2026.
EverSource Wealth Advisors sold 367 Pacira BioSciences shares in Q2 2026, an estimated $8.68K.
Pacira BioSciences made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3658 holding.
EverSource Wealth Advisors first reported a position in Pacira BioSciences in Q4 2021 and has held it in 13 quarters since.
EverSource Wealth Advisors's Pacira BioSciences position peaked at $20.4K in Q2 2025.
254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.